Asset Details
Do you wish to reserve the book?
Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model
Do you wish to request the book?
Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model
2025
Overview
The novel anthrax vaccine candidate GC1109, composed of recombinant protective antigen, has shown robust antibody responses and safety in preclinical and clinical studies. However, the assessment of GC1109 vaccine efficacy was limited in a rodent model and could not be applied in clinical studies due to ethical issues. In this study, we aim to provide predictive insights for human applications of GC1109 by examining the correlation between anthrax toxin-neutralizing antibodies (TNAs) and protection against Bacillus anthracis infection in rabbit. The threshold level of TNAs necessary for protection was assessed following subcutaneous (s.c) challenge with lethal B. anthracis spores. In addition, the longevity of immunity in GC1109-vaccinated rabbits was investigated. A positive correlation between TNA levels and survival was observed, indicating their potential as a predictor of protection in humans. The 50 % neutralization factor (NF50) value of 0.5 was associated with a 70 % probability of survival, establishing this value as a surrogate marker for protective efficacy. Long-term protection was confirmed, with the GC1109-vaccinated group exhibiting significantly higher survival rates (91.7 %) than the control group (8.3 %) at 12 months post-vaccination. These findings highlight the protective efficacy and durability of GC1109-induced immunity against lethal B. anthracis challenge. The study supports the continued development of GC1109 as a viable anthrax vaccine candidate and underscores its potential for emergency preparedness in Korea.
•GC1109 showed immunogenicity and protective efficacy in a rabbit model.•A surrogate marker for assessing anthrax vaccine-induced immunity was established.•A 50 % neutralization factor of 0.5 correlated with 70 % survival probability.•Long lasting immunogenicity against lethal anthrax spores were validated.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Anthrax
/ Anthrax - prevention & control
/ Anthrax Vaccines - administration & dosage
/ Anthrax Vaccines - immunology
/ Antibodies, Bacterial - blood
/ Antibodies, Bacterial - immunology
/ Antibodies, Neutralizing - blood
/ Antibodies, Neutralizing - immunology
/ Antigens
/ Antigens, Bacterial - genetics
/ Antigens, Bacterial - immunology
/ Bacillus anthracis - immunology
/ Bacterial Toxins - immunology
/ ethics
/ Female
/ GC1109
/ humans
/ Immunity
/ Rabbits
/ Serology
/ Spores
/ Survival
/ Toxin neutralization activity
/ Toxins
/ Vaccines
